Case Report

A case of severe acute respiratory syndrome coronavirus 2 with acute thrombotic cerebral infarction and generalized thrombosis

Sylvia Nikolaeva Genova¹, Mina Miroslavova Pencheva², Alexander Georgiev Ivanov³

From ¹Associate Professor, Department of General and Clinical Pathology, Medical University, Faculty of Medicine, University Multiprofile Hospital for Active Medical Treatment “Sveti Georgi”, ²Senior Assistant Professor, Department of Medical Physics and Biophysics, Medical University-Plovdiv, ³Assistant Professor, Department of General and Clinical Pathology, Medical University, Faculty of Medicine, University Multiprofile Hospital for Active Medical Treatment “Sveti Georgi”, Plovdiv, Bulgaria

ABSTRACT

The full spectrum of coronavirus disease 2019 (COVID-19) has not been fully described yet. COVID-19 is associated with a high risk of thrombotic complications such as venous thromboembolism and cerebrovascular disease. Here, we report an autopsy case of a 55-year-old woman diagnosed with severe viral pneumonia complicated by acute cerebral infarction and venous and arterial thrombosis in different organs. The patient died due to severe acute respiratory syndrome coronavirus 2. Macroscopically and histologically, in addition to viral pneumonia and diffuse hemorrhages, fibrin clots were found in arteries and venous vessels of medium and large size in the brain, lungs, and pancreas. Propagation of cerebrovascular thrombosis has led to extensive cerebral infarction. The dating of this infarction, according to the macroscopical findings and the histological changes, was between 24 and 48 h before death. This case confirms the hypothesis on the risk of generalized arterial and venous thromboses in coronavirus infection.

Key words: Autopsy case, Brain infarction, Coronavirus disease 2019 pneumonia, Generalized thrombosis

A n acute respiratory disease, caused by a novel coronavirus (severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2], previously known as 2019-nCoV), the coronavirus disease 2019 (COVID-19) has caused a pandemic spread throughout the world [1]. The full spectrum of COVID-19 has not been fully described yet. COVID-19 is associated with a high risk of thrombotic complications such as venous thromboembolism and cerebrovascular disease. Many patients with severe coronavirus infection have been reported to be in a hypercoagulable state and to develop complications such as venous and arterial thrombosis [2,3]. Some authors describe a different spectrum of neurological manifestations such as brain stroke, neuromuscular disorders, and meningoencephalitis.

Here, we report an autopsy case of a 55-year-old woman diagnosed with severe viral pneumonia complicated by acute cerebral infarction and venous and arterial thrombosis in different organs.

CASE REPORT

A 55-year-old Bulgarian woman complained of weakness, coughing, inability to expectorate, and fever for the past 3 days. The patient had moderate arterial hypertension as an accompanying disease. Antibiotic treatment was prescribed by the general practitioner but the fever persisted and shortness of breath occurred. A week later, her state continued to worsen, with fever (as high as 38°C), dry cough, generalized weakness, and shortness of breath.

The patient was admitted to the Pulmonology department where the patient was diagnosed with pneumonia. The administered treatment included Oseltamivir – 2 mg × 75 mg, Vaborbactam 3 g × 1 g i.v., Levofloxacin 500 mg i.v daily. After 4 days of treatment with no effect and exacerbation of the symptoms, she was transferred to the intensive care unit with confluent, bilateral pneumonia. Auscultation revealed exaggerated vesicular breathing with diffuse wheezing at both lung bases.

The X-ray demonstrated non-homogenous striped shadows in the lower and middle lung parts and around the hilus, while the hilar spaces were congested. The arterial blood pressure gradually rose up to 180/100 Hg. A diagnosis of COVID-19 was confirmed by polymerase chain reaction. Rapid antibody test (IgM, IgA) against SARS-CoV-2 was positive. During the hospital stay, clinical laboratory parameters from the routine blood tests were indicated (Table 1). Blood gas analysis showed an extreme decrease in oxygen saturation in tissue and blood plasma with a decompensated respiratory alkalosis (Table 2).
The following medical procedures were performed during hospitalization: Orotracheal intubation, assisted ventilation, central venous catheter, urethral catheterization. Despite the treatment used, her condition deteriorated and 10 days since the onset of the disease her state became critical and she died.

A complete autopsy of the patient was performed. The mucosae of the trachea and bronchi were hyperemic, their walls were thickened. In their lumens, there was a bloody, mucus matter. Macroscopically, the lungs were enlarged, each one weighing 750 g, with a purple-red color and soft, easily torn consistency. Some nodular areas showed increased density. The cut surface was dark red, with diffuse hemorrhages. Dark purple thrombi were coming out from the blood vessels. The brain was highly edematous. A massive zone of tissue softening involving almost the entire left hemisphere and indicate massive anemic brain infarction was noticeable. Macroscopically, in one of the basal blood vessels, propagated thrombosis was observed. Propagation of thrombosis was observed along the arterial vessels in cerebri posterior and cerebri media. In the same vessels, any atherosclerotic changes were not observed. The cerebral ventricles were not clearly distinguishable because of colliquative necrosis (Fig. 1a). The heart was normally situated in the chest, of normal shape and size. The pericardial sheets and epicardium were smooth, shiny, and translucent. The thickness of the heart chamber, just below the mitral valve was 20 mm (sign of myocardial hypertrophy). The cut surface clearly showed the thickening of the muscle fibers. The papillary muscles were mobile. On dissection, the coronary arteries and other branches of the upper aorta were unaffected by the pathological changes.

The histological picture in the lungs was of a desquamative viral pneumonia and the formation of syncytial structures from alveolocytes (Fig. 2a). The histological picture in the lungs was of a hemorrhagic desquamative giant-cell viral pneumonia and the formation of syncytial structures from alveolocytes (Fig. 2b). Lots of fibrin thrombi were found, mostly in the medium-sized veins and arteries (Fig. 2c). Fibrin thrombi were also found in the medium-sized veins and arteries of other organs, Yellowish areas of gelatinous plaques were found along the intima of the abdominal aorta without the presence of fully developed atherosclerotic plaques. The liver had a normal shape, with slightly increased size. The capsule was smooth, shiny, evenly stretched in all directions, with dense consistency. The cut surface was variegated, brownishyellow, and the lobular structure was not clearly visible. The gallbladder was situated normally, with bile contents, without concretions. The pancreas was of normal location, shape, and size. The cut surface was coarse-grained. The surface of the kidneys was finely granulated with several small serous urinary cysts. The vacant adipose tissue was increased in the hilus. The cortex was slightly atrophic, and the boundary between it and the medulla was not clearly distinguishable. The ureters revealed no visible pathological changes and flowed properly into the bladder. The immediate cause of death was determined to be acute dilatation of the right heart cavities and acute cor pulmonale due to viral pneumonia with SARS-CoV-2-syndrome and acute extensive, thrombotic brain infarction in the left cerebral hemisphere. Other findings related to the cause of death were severe vascular hyperemia and focal hemorrhages in the internal organs, initial chronic venous stasis in the liver and generalized vascular thrombosis in the lungs, pancreas, and brain.

Histologically, the brain tissue was loose, necrotic, with perivasal and pericellular edema. A large propagated thrombus was found in arterial blood vessels, which has caused a vast brain infarction in the left cerebral hemisphere (Fig. 1b and c). In the lungs, multiple desquamated alveolocytes were found, with minimal inflammatory infiltrate. Alveolar walls were with hyperemia and diffuse hemorrhages per diapedesin, hyaline membranes, and multinucleated virus-transformed cells (Fig. 2a). The histological picture in the lungs was of a hemorrhagic desquamative giant-cell viral pneumonia and the formation of syncytial structures from alveolocytes (Fig. 2b). Lactate dehydrogenase

Table 1: Routine blood tests and differential blood count

<table>
<thead>
<tr>
<th>Routine blood tests</th>
<th>Value</th>
<th>Ref</th>
</tr>
</thead>
<tbody>
<tr>
<td>Creatin Kinase</td>
<td>712 U/l</td>
<td>22–198 U/l</td>
</tr>
<tr>
<td>Lactate dehydrogenase</td>
<td>1402 U/l</td>
<td>140–280 U/l</td>
</tr>
<tr>
<td>Activated partial thromboplastin time</td>
<td>29.6s</td>
<td>30–40s</td>
</tr>
<tr>
<td>Fibrinogen</td>
<td>4.15 g/l</td>
<td>2–4 g/l</td>
</tr>
<tr>
<td>D-Dimers</td>
<td>2.960 μg/ml</td>
<td>0–0.5 μg/ml</td>
</tr>
<tr>
<td>C-reactive protein</td>
<td>88 mg/l</td>
<td>0–8 mg/l</td>
</tr>
<tr>
<td>Lymphocytes</td>
<td>0.49%</td>
<td>25–45%</td>
</tr>
<tr>
<td>Eosinophils</td>
<td>0.0–10%</td>
<td>30–350</td>
</tr>
<tr>
<td>Monocytes</td>
<td>0.11%</td>
<td>2–8%</td>
</tr>
</tbody>
</table>

Table 2: Blood gas analysis test

<table>
<thead>
<tr>
<th>Blood gas analysis test</th>
<th>Value</th>
<th>Ref</th>
</tr>
</thead>
<tbody>
<tr>
<td>pCO2 (T)</td>
<td>29.0 mmHg</td>
<td>35–45 mmHg</td>
</tr>
<tr>
<td>pO2 (T)</td>
<td>55.0–59.0 mmHg</td>
<td>&gt;79</td>
</tr>
<tr>
<td>cBase. B.oc) c-AB</td>
<td>4.0 mEq/l</td>
<td>–2–+2 mEq/l</td>
</tr>
<tr>
<td>cBase (Ecf) c-SBE</td>
<td>2.0 mmol/l</td>
<td>–3–+3 mmol/l</td>
</tr>
<tr>
<td>CBASE</td>
<td>–1 mmol/l</td>
<td>–3–+3 mmol/l</td>
</tr>
<tr>
<td>chHCO3-(P, st) c-SBC</td>
<td>27.0 mEq/l</td>
<td>22–26 mEq/l</td>
</tr>
<tr>
<td>ctCO2(b) c-tCO2</td>
<td>26.0 mmol/l</td>
<td>23–30 mmol/l</td>
</tr>
<tr>
<td>pH (T)</td>
<td>7.55</td>
<td>7.35–7.45</td>
</tr>
</tbody>
</table>

Figure 1: (a) Propagating thrombosis in the blood vessels of the brain, a. cerebri posterior (arrow), a. cerebri media (double arrow). Infarcted area*. Gross picture; (b) Fibrin thrombus in a. cerebri posterior of the brain (H and E, Original magn. ×40); (c) Fibrin thrombus in a. cerebri media (H and E, Original magn. ×40)
explained that the early pathogenesis in COVID-19 pneumonia was defined by widespread endothelialitis affecting multiple organ systems. Analysis of precapillary vessels showed that in four of the seven lungs from patients with COVID-19, thrombi were consistently present in pulmonary arteries with a diameter of 1–2 mm, without complete luminal obstruction [6]. At the same time, systemic inflammation is commonly observed, with elevated levels of C-reactive protein, fibrinogen, and cytokines such as interleukin-6 [7]. These include the increased production of tissue factors and amplification of the coagulation cascade, resulting in increased production of thrombin and fibrin. Clot formation is extremely rapid and also resistant to breakdown [8].

The high rate of pulmonary thrombosis in COVID-19 conceivably lies in the coalescence of several mechanisms which disturb Virchow’s triad within the lungs: The intense endothelial inflammation, leading to “in situ” thrombosis, including microvascular thrombosis and altered pulmonary blood flow in response to the parenchymal process [9,10]. The presumed pathogenic mechanism is also schematically described by Price et al. [10] as when coronavirus infects cells, active replication and release of the virus may cause the host cell to undergo pyroptosis and release DAMPs, activating oxidant stress, and generating pro-inflammatory cytokine and chemokine release from nearby epithelial cells, endothelial cells and alveolar macrophage [10-12].

Besides pulmonary thrombosis, increased brain involvement is also described in the literature, such as brain stroke, neuromuscular disorders, and meningoencephalitis. A large study by Ghannam et al. [11] showed that 87.5% of the cerebrovascular infarctions were due to ischemic strokes followed by cerebral vein thrombosis (5%), intracerebral hemorrhages (5%). In the review, ischemic stroke was the most common neurological manifestation, occurring in 42.7% of the subjects, with large vessel occlusion representing 77% of the ischemic stroke [11,12].

In the literature, there are a few published cases of cerebral thrombosis, most of them reported by radiologists, using mainly computed tomography imaging [12]. Sugiyama et al. [13] demonstrated cerebral thrombosis in the left transverse sinus. Zhou et al. [14] reported a case of a 75-year-old woman diagnosed with severe COVID-19, complicated by acute cerebral infarction and venous thrombosis of the bilateral lower extremities.

DISCUSSION

SARS-CoV-2 belongs to β-coronavirus and has been shown to enter cells through binding with ACE-2 receptors, found mainly on the membrane of the alveolar epithelium and endothelium. Activation of endothelial cells is thought to be the primary driver for the increasingly recognized complication of thrombosis [1,2]. The immune dysregulation characteristic of severe COVID-19 infection may be initiated by “pyroptosis,” a particularly pro-inflammatory form of apoptosis [2,3]. In most cases, there is also an elevation in the D-dimers. In the presented case the D-dimers, fibrinogen, activated partial thromboplastin time were increased by multiple times.

In COVID infection, there is a high correlation between pulmonary thrombosis and SARS syndrome in the lungs [4]. Huertas et al. [5] explained that the early pathogenesis in

COVID-19 pneumonia was defined by widespread endothelialitis affecting multiple organ systems. Analysis of precapillary vessels showed that in four of the seven lungs from patients with COVID-19, thrombi were consistently present in pulmonary arteries with a diameter of 1–2 mm, without complete luminal obstruction [6]. At the same time, systemic inflammation is commonly observed, with elevated levels of C-reactive protein, fibrinogen, and cytokines such as interleukin-6 [7]. These include the increased production of tissue factors and amplification of the coagulation cascade, resulting in increased production of thrombin and fibrin. Clot formation is extremely rapid and also resistant to breakdown [8].

The high rate of pulmonary thrombosis in COVID-19 conceivably lies in the coalescence of several mechanisms which disturb Virchow’s triad within the lungs: The intense endothelial inflammation, leading to “in situ” thrombosis, including microvascular thrombosis and altered pulmonary blood flow in response to the parenchymal process [9,10]. The presumed pathogenic mechanism is also schematically described by Price et al. [10] as when coronavirus infects cells, active replication and release of the virus may cause the host cell to undergo pyroptosis and release DAMPs, activating oxidant stress, and generating pro-inflammatory cytokine and chemokine release from nearby epithelial cells, endothelial cells and alveolar macrophage [10-12].

Besides pulmonary thrombosis, increased brain involvement is also described in the literature, such as brain stroke, neuromuscular disorders, and meningoencephalitis. A large study by Ghannam et al. [11] showed that 87.5% of the cerebrovascular infarctions were due to ischemic strokes followed by cerebral vein thrombosis (5%), intracerebral hemorrhages (5%). In the review, ischemic stroke was the most common neurological manifestation, occurring in 42.7% of the subjects, with large vessel occlusion representing 77% of the ischemic stroke [11,12].

In the literature, there are a few published cases of cerebral thrombosis, most of them reported by radiologists, using mainly computed tomography imaging [12]. Sugiyama et al. [13] demonstrated cerebral thrombosis in the left transverse sinus. Zhou et al. [14] reported a case of a 75-year-old woman diagnosed with severe COVID-19, complicated by acute cerebral infarction and venous thrombosis of the bilateral lower extremities.
AUTHOR CONTRIBUTORS

S.N.G., M.M.P., A.G.I. designing study, acquiring data, analyzing data, writing manuscript. All authors participated in revising and approving the manuscript.

ACKNOWLEDGMENTS

The authors express their gratitude to Assoc. Prof. Bivolarsky for aiding in the diagnosis of the case and to Dr. Popivanova for providing macroscopic photo.

REFERENCES